Royce & Associates LP Has $9.42 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Royce & Associates LP increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 58.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 196,999 shares of the biopharmaceutical company’s stock after acquiring an additional 72,988 shares during the quarter. Royce & Associates LP’s holdings in Halozyme Therapeutics were worth $9,419,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $21,838,000. Janney Montgomery Scott LLC raised its holdings in Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after purchasing an additional 243,940 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after purchasing an additional 191,465 shares during the last quarter. Finally, Hantz Financial Services Inc. acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $9,260,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company’s stock, valued at $1,972,629.59. The trade was a 12.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 in the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.7 %

Shares of HALO stock opened at $62.54 on Wednesday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market capitalization of $7.70 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a 50-day simple moving average of $57.53 and a two-hundred day simple moving average of $54.61.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.